Articles tagged "Highly-sensitized"

2022 American Transplant Congress
Perturbing Proteostasis to Deplete Plasma Cells
A. Rossi¹, A. Burg¹, K. Roskin¹, A. Shields², R. Alloway², E. Woodle², D. Hildeman¹
¹Cincinnati Children's Hospital, Cincinnati, OH, ²University of Cincinnati College of Medicine, Cincinnati, OH
*Purpose: Alloantibodies play critical roles in rejection and often prevent sensitized patients from receiving life-sustaining transplants. One approach for enhancing transplantation rates and survival for…
2022 American Transplant Congress
Complement 5 Regulation Ameliorates Antibody-Mediated Rejection After Liver Transplantation in Rats
T. Tajima¹, K. Hata¹, J. Kusakabe¹, H. Miyauchi¹, X. Zhao¹, S. Kageyama¹, T. Okamoto¹, Y. Wang², E. Hatano¹
¹Dept. of HBP Surgery & Transplantation, Kyoto University, Kyoto, Japan, ²Alexion Pharmaceuticals Inc., New Haven, CT
*Purpose: Antibody-mediated rejection (AMR) is a refractory rejection after donor-specific antibody (DSA)-positive or blood-type incompatible organ transplantation. Since AMR significantly deteriorates transplant outcomes, there is…
2022 American Transplant Congress
Regulatory T Cells Suppress Memory IL-17a Production in Highly Sensitised Patients with End-Stage Renal Disease
C. Dudreuilh¹, S. Basu¹, O. Shaw², H. Burton¹, C. Domingo-Vila¹, T. Tree¹, G. Lombardi¹, C. Scotta¹, A. Dorling¹
¹King's College London, London, United Kingdom, ²Viapath Clinical Transplantation Laboratory, Guy's Hospital, London, United Kingdom
*Purpose: Highly sensitised patients exhibit poorer long-term outcomes following renal transplantation compared to those non sensitised individuals. IL17-A has been associated with acute rejection. Presence…
2022 American Transplant Congress
Reduced CD45RA-CCR7- Tregs Subtypes in Highly Sensitised Patients Associates with a Failure to Regulate Memory IFNγ Production in Response to Donor Alloantigens
C. Dudreuilh¹, S. Basu¹, O. Shaw², H. Burton¹, C. Domingo-Vila¹, T. Tree¹, G. Lombardi¹, C. Scotta¹, A. Dorling¹
¹King's College London, London, United Kingdom, ²Viapath Clinical Transplantation Laboratory, Guy's Hospital, London, United Kingdom
*Purpose: Highly sensitised (HS) patients exhibit worse long-term outcomes after kidney transplantation compared to non-sensitised patients. It has been hypothesised that regulatory T cells (Tregs)…
2022 American Transplant Congress
Regulatory T Cells Suppress Memory IFN-Gamma Production in Highly Sensitised Patients
C. Dudreuilh¹, S. Basu¹, O. Shaw², H. Burton¹, C. Domingo-Vila¹, T. Tree¹, G. Lombardi¹, C. Scotta¹, A. Dorling¹
¹King's College London, London, United Kingdom, ²Viapath Clinical Transplantation Laboratory, Guy's Hospital, London, United Kingdom
*Purpose: Highly sensitized patients (HS) present worse long-term outcome after transplantation compared to those without donor-specific antibodies (DSA). It has been suggested that desensitisation using…
2022 American Transplant Congress
Clazakizumab® (anti-il-6) Desensitization in Highly-HLA Sensitized Patients Awaiting Kidney Transplant (nct03380962): Long-Term Follow Up
A. Vo¹, J. Tang¹, N. Ammerman¹, E. Huang¹, X. Zhang², M. Haas³, A. Peng¹, R. Najjar¹, S. Williamson¹, C. Meyers¹, S. Sethi¹, K. Lim¹, M. Gillespie¹, N. Badash¹, S. Jordan¹
¹Comprehensive Transplant Center, Cedars Sinai Medical Ctr, Los Angeles, CA, ²HLA Laboratory, Cedars Sinai Medical Ctr, Los Angeles, CA, ³Pathology, Cedars Sinai Medical Ctr, Los Angeles, CA
*Purpose: IL-6 is a cytokine critical for B-cell activation and IgG production. Clazakizumab (CSL Behring LLC) is a humanized monoclonal aimed at the cytokine IL-6.…
2022 American Transplant Congress
CIAT: A New Kidney Exchange Program with Better Options for Highly Sensitized and Long Waiting Patients
M. d. Klerk¹, J. Kal¹, D. L. Roelen², M. Betjes¹, A. Weerd de¹, M. Reinders¹, M. Kho¹, K. Glorie³, J. I. Roodnat¹
¹Internal Medicine, Erasmus MC Transplant Institute, Rotterdam, Netherlands, ²Immunology, Leids UMC, Netherlands, ³Econometrics, EUR, Rotterdam, Netherlands
*Purpose: A number of alternative, both living and deceased donor kidney transplant programs have been developed for incompatible pairs and difficult to match patients. The…
2022 American Transplant Congress
Evaluation of Hepatitis C Positive Donor to Hepatitis C Negative Recipient Kidney Transplant in a Highly Sensitized Patient Population
A. T. Iaria, M. Martin, A. Hietpas, I. Tang, S. Koppe, I. Tzvetanov, E. Benedetti, C. Muran
University of Illinois at Chicago, Chicago, IL
*Purpose: This study assessed outcomes of hepatitis C virus (HCV) donor positive to recipient negative (D+/R-) kidney transplants (KT) in high immunologic risk patients. Literature…
2022 American Transplant Congress
Viral-Specific Cytotoxic T-Cell Responses in Hla-Sensitized Kidney Transplant Patients Maintained on Everolimus and Low Dose Tacrolimus
R. Zhang¹, S. Ge¹, M. Chu¹, J. Kahwaji², A. Karasyov¹, D. Lovato¹, A. Vo², J. Choi², M. Toyoda¹, S. Jordan²
¹Transplant Immunology Laboratory, Cedars Sinai Medical Center, Los Angeles, CA, ²Comprehensive Transplant Center, Cedars Sinai Medical Center, Los Angeles, CA
*Purpose: Post-transplant immunosuppression with “everolimus + reduced dose tacrolimus” (Ev + Taclow) is reported to reduce the risk of viral infections compared to standard doses…
2022 American Transplant Congress
Stem Cell Donor-Derived CPRA Better Reflects Sensitization Than Current CPRA
K. Lindblad¹, C. Murphey², P. Lalli³, J. Lunz⁴, L. Gragert⁵
¹UNOS, Richmnd, VA, ²Southwest Immunodiagnostics, Inc., San Antonio, TX, ³Carolinas Medical Center, Charlotte, NC, ⁴LifeLink Foundation Transplant Immunology Lab, Tampa, FL, ⁵Tulane University School of Medicine, New Orleans, LA
*Purpose: The OPTN Histocompatibility Committee proposes replacing the current calculated panel reactive antibody (CPRA), based on HLA haplotype frequencies from ~14,000 deceased kidney donors, with…

1
2
3
…
15
Next Page »